15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.2B | $732000 | 36.8% | 1.9% | $92M | $1.3B | $308M |
| 2024 | $2.4B | -$118M | 34.6% | 1.8% | $125M | $1.6B | $309M |
| 2023 | $2.3B | -$30M | 32.8% | 1.0% | $82M | $1.6B | $254M |
| 2022 | $2.3B | -$74M | 30.6% | -1.9% | -$152M | $1.7B | $209M |
| 2021 | $1.3B | $103M | 37.3% | 9.4% | $199M | $0 | $553M |
| 2020 | $1.3B | $87M | 36.3% | 7.7% | $131M | — | $396M |
| 2019 | $1.3B | $101M | 37.3% | 8.5% | $5M | — | $269M |
| 2018 | $1.4B | $29M | 40.7% | 2.1% | $67M | — | — |
| 2017 | $1.3B | $69M | 33.0% | -1.0% | $80M | — | — |
| 2016 | $379M | $63M | 53.1% | 21.9% | $67M | $0 | — |
| 2015 | $342M | $45M | 52.9% | 20.1% | $51M | — | — |
| 2014 | $309M | $26M | 49.0% | 12.6% | $50M | — | — |
| 2013 | $314M | $40M | 49.3% | 16.6% | $47M | — | — |
| 2012 | $317M | $41M | 49.4% | 19.3% | $47M | — | — |
| 2011 | $302M | $45M | 47.1% | 21.6% | $49M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $530M | $30M | 38.9% | 2.6% | $28M | $1.3B | $288M |
| Sep '25 | $537M | -$3M | 37.4% | 2.6% | $28M | $1.3B | $300M |
| Jun '25 | $549M | $35M | 37.9% | 1.9% | -$8M | $1.3B | $300M |
| Mar '25 | $605M | -$15M | 34.7% | 2.1% | $37M | $1.5B | $290M |
| Sep '24 | $589M | -$33M | 34.8% | 1.4% | $16M | $1.6B | $313M |
| Jun '24 | $596M | -$21M | 34.8% | 1.3% | $62M | $1.6B | $303M |
| Mar '24 | $567M | -$39M | 32.7% | -1.9% | $30M | $1.6B | $251M |
| Sep '23 | $553M | -$39M | 33.2% | 4.1% | $14M | $1.6B | $197M |
| Jun '23 | $549M | -$10M | 35.0% | 0.5% | -$20M | $1.6B | $196M |
| Mar '23 | $569M | -$10M | 33.8% | 1.7% | $27M | $1.6B | $221M |
| Sep '22 | $598M | -$10M | 31.2% | -0.1% | -$18M | $1.7B | $244M |
| Jun '22 | $561M | -$7M | 29.9% | -0.0% | -$86M | $1.7B | $256M |
| Mar '22 | $543M | -$38M | 31.1% | -7.8% | -$25M | $1.7B | $329M |
| Sep '21 | $336M | $31M | 38.0% | 11.4% | $62M | — | $519M |
| Jun '21 | $322M | $28M | 38.4% | 10.7% | $39M | — | $462M |
| Mar '21 | $318M | $24M | 35.4% | 8.4% | $37M | — | $424M |
| Dec '20 | — | $26M | — | — | $49M | — | $396M |
| Sep '20 | $319M | $25M | 35.8% | 8.0% | $52M | — | — |
| Jun '20 | $303M | $19M | 35.0% | 6.4% | $16M | — | — |
| Mar '20 | $329M | $17M | 36.9% | 7.9% | $14M | — | — |
How the market has priced ICUI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Icu Medical Inc/De's revenue has grown 11.9% per year, and net income declined 61.5% per year. These are computed facts, not advice.
As of FY2025, Icu Medical Inc/De reported $1.3B of total debt against $308M of cash; operating income covered interest expense 0.5×.
In FY2025, gross margin was 36.8%, operating margin 1.9%, and net margin 0.0%.
As of Jun '26, Icu Medical Inc/De traded at a price-to-earnings ratio of about 5078.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.